0      0


JL1117ES - JL1117ES: Initial efficacy and safety of RP1 + nivolumab in patients with anti–PD-1–failed melanoma from the ongoing phase 1/2 IGNYTE study


‐ Nov 2, 2023 2:00pm


Presenter(s):

You must be logged in and own this session in order to post comments.